NASDAQ:POAI Predictive Oncology Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Predictive Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.41 0.00 (0.00%) (As of 07/5/2022 12:00 AM ET) Add Compare Share Today's Range$0.40▼$0.4350-Day Range$0.27▼$0.8052-Week Range$0.25▼$1.47Volume165,479 shsAverage Volume366,840 shsMarket Capitalization$27.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Predictive Oncology MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.28% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 2 Articles This WeekInsider TradingAcquiring Shares$126,796 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.06) to ($0.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.08 out of 5 starsMedical Sector1086th out of 1,426 stocksSurgical Appliances & Supplies Industry20th out of 30 stocks 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Predictive Oncology. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.28% of the outstanding shares of Predictive Oncology have been sold short.Short Interest Ratio / Days to CoverPredictive Oncology has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Predictive Oncology has recently decreased by 63.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPredictive Oncology does not currently pay a dividend.Dividend GrowthPredictive Oncology does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for POAI. Previous Next 3.3 News and Social Media Coverage News SentimentPredictive Oncology has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Predictive Oncology this week, compared to 0 articles on an average week.Search Interest9 people have searched for POAI on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Predictive Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Predictive Oncology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $126,796.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.76% of the stock of Predictive Oncology is held by insiders.Percentage Held by InstitutionsOnly 6.23% of the stock of Predictive Oncology is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Predictive Oncology are expected to grow in the coming year, from ($0.06) to ($0.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Predictive Oncology is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Predictive Oncology is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPredictive Oncology has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive POAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Predictive Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address About Predictive Oncology (NASDAQ:POAI) StockPredictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.Read More POAI Stock News HeadlinesJuly 5, 2022 | americanbankingnews.comMilestone Scientific (NYSE:MLSS) and Predictive Oncology (NASDAQ:POAI) Head to Head ContrastJune 6, 2022 | proactiveinvestors.comPredictive Oncology has a flagship AI-powered drug discovery platform to speed up new cancer treatmentsMay 19, 2022 | nasdaq.comPredictive Oncology vs. Bitcoin: Price Relationship Crosses ThresholdMay 19, 2022 | proactiveinvestors.comPredictive Oncology closes two concurrent offerings raising gross proceeds of $7.2MMay 18, 2022 | finance.yahoo.comPredictive Oncology Announces Closing of $7.2 Million Registered Direct OfferingsMay 16, 2022 | seekingalpha.comPredictive Oncology announces $7.2M registered direct offeringMay 16, 2022 | finance.yahoo.comPredictive Oncology Announces $7.2 Million Registered Direct OfferingsMay 13, 2022 | proactiveinvestors.comPredictive Oncology reports sharply higher consolidated revenue in 1Q 2022May 13, 2022 | finance.yahoo.comPredictive Oncology Reports First Quarter Financial ResultsMay 10, 2022 | ca.proactiveinvestors.comPredictive Oncology has an AI-driven drug discovery platform to improve cancer treatments and speed up drug developmentApril 26, 2022 | ca.proactiveinvestors.comPredictive Oncology announces Theresa Ferguson as the company's senior director of MarketingApril 26, 2022 | finance.yahoo.comMarketer with over 20 years of experience selected to head up marketing at Predictive OncologyMarch 31, 2022 | finance.yahoo.comPredictive Oncology Reports Year End 2021 Financial Results and Provides Business UpdateMarch 24, 2022 | finance.yahoo.comPredictive Oncology validates Discovery 21 proof-of-concept campaignMarch 16, 2022 | proactiveinvestors.comPredictive Oncology applies artificial intelligence to the research and development process of personalized cancer therapiesJanuary 27, 2022 | proactiveinvestors.comPredictive Oncology set to market its flagship artificial intelligence drug discovery platformJanuary 27, 2022 | proactiveinvestors.comPredictive Oncology 'has a treasure trove' of information with AI drug discovery platformJanuary 27, 2022 | finance.yahoo.comPredictive Oncology set to market AI drug discovery platformJanuary 25, 2022 | proactiveinvestors.comHC Wainwright reiterates ‘Buy’ rating on Predictive Oncology and $5 price targetJanuary 13, 2022 | seekingalpha.comPredictive Oncology AI program identifies potential cancer drug usesJanuary 13, 2022 | finance.yahoo.comPOAI Reports Strong Results From Its AI Cancer Drug EvaluationDecember 27, 2021 | finance.yahoo.comPredictive Oncology Adjourns Annual Meeting of Stockholders to December 30, 2021December 22, 2021 | finance.yahoo.comPredictive Oncology Inc. (POAI) Upgraded to Buy: What Does It Mean for the Stock?December 21, 2021 | finance.yahoo.comPredictive Oncology – Year-end Shareholder Update!December 20, 2021 | nasdaq.comPredictive OncologySee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:POAI CUSIPN/A CIK1446159 Webwww.precisiontherapeutics.com Phone(651) 389-4800FaxN/AEmployees22Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today7/06/2022Next Earnings (Estimated)8/10/2022Fiscal Year End12/31/2022Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,660,000.00 Net Margins-1,314.56% Pretax Margin-1,359.96% Return on Equity-27.33% Return on Assets-25.39% Debt Debt-to-Equity RatioN/A Current Ratio9.79 Quick Ratio9.62 Sales & Book Value Annual Sales$1.42 million Price / Sales19.25 Cash FlowN/A Price / Cash FlowN/A Book Value$0.61 per share Price / Book0.68Miscellaneous Outstanding Shares66,160,000Free Float65,657,000Market Cap$27.33 million OptionableNot Optionable Beta1.40 Predictive Oncology Frequently Asked Questions Should I buy or sell Predictive Oncology stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Predictive Oncology in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Predictive Oncology stock. View analyst ratings for Predictive Oncology or view top-rated stocks. How has Predictive Oncology's stock performed in 2022? Predictive Oncology's stock was trading at $0.9519 at the start of the year. Since then, POAI shares have decreased by 56.6% and is now trading at $0.4131. View the best growth stocks for 2022 here. When is Predictive Oncology's next earnings date? Predictive Oncology is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for Predictive Oncology. How were Predictive Oncology's earnings last quarter? Predictive Oncology Inc. (NASDAQ:POAI) issued its quarterly earnings data on Thursday, May, 12th. The medical instruments supplier reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by $0.01. The medical instruments supplier earned $0.32 million during the quarter, compared to analyst estimates of $1 million. Predictive Oncology had a negative net margin of 1,314.56% and a negative trailing twelve-month return on equity of 27.33%. View Predictive Oncology's earnings history. Who are Predictive Oncology's key executives? Predictive Oncology's management team includes the following people: Mr. J. Melville Engle, Chairman & CEO (Age 72, Pay $508.57k)Mr. Robert L. Myers, CFO & Sec. (Age 67, Pay $391.96k)Mr. Richard L. Gabriel B.Sc, MBA, Sr. VP of R&D (Age 73, Pay $2.33k)Dr. Lawrence J. DeLucas D.Sc, O.D, Ph.D., Sr. VP of OperationsMs. Theresa Ferguson, Sr. Director of MarketingMs. Pamela Bush M.B.A., Ph.D., Sr. VP of Strategic Sales & Bus. Devel.Dr. Arlette H. Uihlein FCAP, M.D., Sr. VP of Regulatory Affairs & QualityDr. Julia Kirshner Ph.D., Pres of zPredicta Who are some of Predictive Oncology's key competitors? Some companies that are related to Predictive Oncology include United Health Products (UEEC), Milestone Scientific (MLSS), Milestone Scientific (MLSS), Conformis (CFMS), ReWalk Robotics (RWLK), Alpha Pro Tech (APT), Alpha Pro Tech (APT), Sientra (SIEN), Invacare (IVC), Nutriband (NTRB), Eargo (EAR), Surgalign (SRGA), NanoVibronix (NAOV), Bone Biologics (BBLG) and Myomo (MYO). View all of POAI's competitors. What other stocks do shareholders of Predictive Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Predictive Oncology investors own include NVIDIA (NVDA), OPKO Health (OPK), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Overstock.com (OSTK), Riot Blockchain (RIOT), AcelRx Pharmaceuticals (ACRX), Boeing (BA), QUALCOMM (QCOM) and Sorrento Therapeutics (SRNE). What is Predictive Oncology's stock symbol? Predictive Oncology trades on the NASDAQ under the ticker symbol "POAI." How do I buy shares of Predictive Oncology? Shares of POAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Predictive Oncology's stock price today? One share of POAI stock can currently be purchased for approximately $0.41. How much money does Predictive Oncology make? Predictive Oncology (NASDAQ:POAI) has a market capitalization of $27.33 million and generates $1.42 million in revenue each year. The medical instruments supplier earns $-19,660,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis. How many employees does Predictive Oncology have? Predictive Oncology employs 22 workers across the globe. How can I contact Predictive Oncology? Predictive Oncology's mailing address is 2915 COMMERS DRIVE SUITE 900, EAGAN MN, 55121. The official website for Predictive Oncology is www.precisiontherapeutics.com. The medical instruments supplier can be reached via phone at (651) 389-4800 or via email at james@haydenir.com. This page (NASDAQ:POAI) was last updated on 7/6/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
